Closer Look at Therapeutic Interventional Clinical Trials in Multiple Myeloma
Posted: Tuesday, August 14, 2018
For the enhancement of personal and professional knowledge of oncologists, particularly those specializing in patients with multiple myeloma, Peter M. Barth, MD, of the Department of Medicine, Division of Hematology/Oncology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, and colleagues made quite a contribution. Their analysis, published in Future Oncology, focused on 239 therapeutic interventional clinical trials in multiple myeloma. And, even more so, they characterized the trials according to trial phase, quality-of-life assessment, type of intervention, and sponsor.
The researchers gathered their data from ClinicalTrials.gov. The majority of trials (84.1%) were centered on early-phase immunotherapies. Of note, the quality of assessment was included in just 10% of the trials. Their findings also provided insight to some of the forward-looking suggestions offered by researchers, including the need for continued advancement of immunotherapies, late-phase studies utilizing a triplet control group, and an objective focus on quality of life.
“The therapeutic armamentarium for multiple myeloma has grown significantly over the past decade,”the investigators noted. “Thus, we felt a need to place this growth in a proper and updated perspective.”
